See more : Chung Hwa Pulp Corporation (1905.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beijing Konruns Pharmaceutical Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Redwood Financial, Inc. (REDW) Income Statement Analysis – Financial Results
- 4Cable TV International, Inc. (CATV) Income Statement Analysis – Financial Results
- Netfonds AG (NF4.DE) Income Statement Analysis – Financial Results
- Ning Xia Yin Xing Energy Co.,Ltd (000862.SZ) Income Statement Analysis – Financial Results
- J. Front Retailing Co., Ltd. (3086.T) Income Statement Analysis – Financial Results
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
About Beijing Konruns Pharmaceutical Co.,Ltd.
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and KC1036. The company was founded in 2003 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 920.01M | 866.73M | 809.78M | 808.64M | 1.07B | 1.02B | 590.58M | 346.23M | 436.15M | 544.49M | 598.38M |
| Cost of Revenue | 101.05M | 126.16M | 105.76M | 59.25M | 57.66M | 50.05M | 44.97M | 38.18M | 41.22M | 35.58M | 29.79M |
| Gross Profit | 818.96M | 740.57M | 704.02M | 749.40M | 1.01B | 972.12M | 545.61M | 308.04M | 394.93M | 508.91M | 568.60M |
| Gross Profit Ratio | 89.02% | 85.44% | 86.94% | 92.67% | 94.59% | 95.10% | 92.39% | 88.97% | 90.55% | 93.47% | 95.02% |
| Research & Development | 94.91M | 86.78M | 102.27M | 93.11M | 108.78M | 80.25M | 32.17M | 38.39M | 38.73M | 0.00 | 0.00 |
| General & Administrative | 39.58M | 33.15M | 32.20M | 24.83M | 8.67M | 13.63M | 7.90M | 5.43M | 32.73M | 65.76M | 64.07M |
| Selling & Marketing | 472.59M | 423.15M | 391.28M | 473.15M | 637.20M | 602.90M | 291.31M | 76.98M | 133.78M | 270.58M | 382.64M |
| SG&A | 512.17M | 456.30M | 423.49M | 497.98M | 645.87M | 616.52M | 299.21M | 82.41M | 166.51M | 336.34M | 446.71M |
| Other Expenses | 68.60M | 60.27M | 45.48M | 9.66M | 12.27M | 175.29K | 18.40M | 10.33M | 18.67M | 12.80M | 17.19M |
| Operating Expenses | 675.68M | 603.34M | 571.24M | 600.75M | 766.93M | 708.32M | 354.00M | 145.56M | 230.28M | 344.86M | 456.39M |
| Cost & Expenses | 776.73M | 729.50M | 677.00M | 660.00M | 824.59M | 758.37M | 398.97M | 183.74M | 271.50M | 380.44M | 486.18M |
| Interest Income | 13.77M | 18.52M | 24.57M | 48.63M | 62.29M | 35.13M | 11.23M | 1.03M | 186.26K | 386.00K | 638.00K |
| Interest Expense | 2.39M | 864.06K | 1.41M | 418.42K | 27.21K | 35.11M | 11.21M | 12.95K | 19.92K | 20.30K | 331.46K |
| Depreciation & Amortization | 42.94M | 39.27M | 36.23M | 30.04M | 34.66M | 34.56M | 26.79M | 26.53M | 24.97M | 22.25M | 16.22M |
| EBITDA | 168.07M | 189.97M | 226.10M | 238.85M | 240.24M | 334.79M | 246.02M | 217.13M | 189.62M | 186.30M | 139.35M |
| EBITDA Ratio | 18.27% | 21.49% | 27.90% | 29.23% | 27.11% | 29.99% | 37.40% | 54.84% | 43.44% | 34.85% | 21.46% |
| Operating Income | 143.28M | 140.70M | 192.29M | 210.22M | 299.51M | 300.04M | 556.91M | 207.84M | 203.75M | 190.39M | 118.72M |
| Operating Income Ratio | 15.57% | 16.23% | 23.75% | 26.00% | 28.10% | 29.35% | 94.30% | 60.03% | 46.72% | 34.97% | 19.84% |
| Total Other Income/Expenses | -20.55M | -386.93K | -3.44M | -2.20M | -420.03K | 175.29K | 18.20M | 10.33M | 18.67M | 9.12M | 16.79M |
| Income Before Tax | 122.73M | 140.32M | 188.86M | 208.02M | 299.09M | 300.21M | 575.31M | 218.18M | 222.42M | 199.51M | 135.51M |
| Income Before Tax Ratio | 13.34% | 16.19% | 23.32% | 25.73% | 28.06% | 29.37% | 97.41% | 63.02% | 51.00% | 36.64% | 22.65% |
| Income Tax Expense | -64.84M | 16.42M | 21.42M | 24.67M | 33.01M | 36.28M | 96.49M | 26.52M | 27.17M | 23.65M | 16.57M |
| Net Income | 150.45M | 101.49M | 147.99M | 183.36M | 266.08M | 263.93M | 478.82M | 191.65M | 195.25M | 175.90M | 118.44M |
| Net Income Ratio | 16.35% | 11.71% | 18.27% | 22.67% | 24.96% | 25.82% | 81.08% | 55.36% | 44.77% | 32.30% | 19.79% |
| EPS | 0.96 | 0.65 | 0.94 | 1.15 | 1.66 | 1.98 | 3.99 | 1.60 | 1.63 | 1.47 | 0.99 |
| EPS Diluted | 0.96 | 0.65 | 0.94 | 1.15 | 1.66 | 1.98 | 3.99 | 1.60 | 1.63 | 1.47 | 0.99 |
| Weighted Avg Shares Out | 156.72M | 156.49M | 157.43M | 160.00M | 160.00M | 133.30M | 120.00M | 119.78M | 119.79M | 119.66M | 119.63M |
| Weighted Avg Shares Out (Dil) | 156.72M | 156.49M | 157.43M | 160.00M | 160.00M | 133.30M | 120.00M | 119.78M | 119.79M | 119.66M | 119.63M |
Source: https://incomestatements.info
Category: Stock Reports